GlassScriptPhysician profile
John Ruck
NPI 1336688456
$6,332.65
in general payments reported to CMS, 2019-2025
20 companies · $95.47 in 2025
The $95.47 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,941 · 2022: $1,130 · 2023: $211 · 2024: $2,955 · 2025: $95.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,439 · Food and Beverage: $823.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,439.00 |
| Food and Beverage | $822.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $2,928.30 | 2021-2024 | |
| Lifescan, INC. | $1,060.00 | 2022 | |
| Lilly USA, LLC | $510.07 | 2021-2024 | Mounjaro |
| Dexcom, INC. | $398.19 | 2021-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $338.10 | 2021 | |
| Novo Nordisk INC | $222.28 | 2021 | |
| Amarin Pharma, INC. | $220.73 | 2021 | |
| Corcept Therapeutics | $125.76 | 2021 | |
| Ascensia Diabetes Care US INC. | $108.59 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.52 | 2021 | |
| Merck Sharp & Dohme LLC | $91.04 | 2021 | |
| Zealand Pharma US, INC. | $43.74 | 2021 | |
| Ibsa Pharma INC. | $36.55 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.59 | 2021 | |
| Abbvie INC. | $26.66 | 2022-2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $19.61 | 2021 | |
| Xeris Pharmaceuticals, INC. | $18.11 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.20 | 2021 | |
| Insulet Corporation | $16.43 | 2021 | |
| Amgen INC. | $14.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ruck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.